Boston Scientific Corp (XTER:BSX)
€ 86.5 -0.5 (-0.57%) Market Cap: 126.52 Bil Enterprise Value: 134.81 Bil PE Ratio: 74.93 PB Ratio: 6.45 GF Score: 79/100

Boston Scientific Corp Investor Update at Vascular Interventional Advances Conference (VIVA) Transcript

Nov 05, 2019 / 07:00PM GMT
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Boston Scientific Investor update at VIVA 2019 Conference Call. (Operator Instructions).

Also a reminder, today's teleconference is being recorded. At this time, I will turn the call over to your host, VP of Investor Relations, Ms. Susie Lisa. Please go ahead.

Susan Vissers Lisa
Boston Scientific Corporation - VP of IR

Thank you, Tony. And thanks, everyone, for joining us for VIVA update from our Peripheral Interventions team.

Good morning to those of you in Vegas, and good afternoon elsewhere here on the East Coast.

We'll start -- we'll jump right in, but I would first like to introduce our lineup, including Jeff Mirviss, whom you all know well, our Senior Vice President and President of our Peripheral Interventions business. He is joined by Cat Jennings, our VP of Marketing and Business Development. And then we have a new member of the team, I'm very pleased to introduce Dr. Michael Jaff, who is the incoming Vice President of Clinical Affairs, Innovation and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot